Welcome to our dedicated page for Ani Pharmaceutic news (Ticker: ANIP), a resource for investors and traders seeking the latest updates and insights on Ani Pharmaceutic stock.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company with an active flow of corporate, clinical, and financial news. The company develops, manufactures, and commercializes therapeutics through its Rare Disease, Generics, and Brands businesses, and its communications frequently highlight progress in these areas. Investors following ANIP news can track how the Rare Disease segment, including products such as ILUVIEN and Purified Cortrophin Gel, contributes to the company’s growth alongside its generics and branded drug portfolios.
News updates for ANI often cover financial results and guidance, including quarterly earnings releases, adjusted non-GAAP metrics, and full-year outlooks. Press releases and related Form 8-K filings provide detail on net revenues by segment, the performance of key products, and management’s commentary on business trends. These disclosures also outline how Rare Disease revenues, particularly from Cortrophin Gel and ILUVIEN, compare with contributions from Generics and Brands.
ANIP news also includes clinical and medical developments, such as results from the NEW DAY clinical trial of ILUVIEN in diabetic macular edema and their presentation at major ophthalmology and retina meetings. The company reports on initiatives like the FutureVision Advisory Council, a group of retina and uveitis specialists formed to help guide its ophthalmology and retina franchise. Updates on Phase 4 trials, label transitions, and adoption trends for ILUVIEN and related products are also featured.
In addition, ANI regularly announces corporate and governance updates, including board transitions and leadership roles, as well as participation in healthcare and investor conferences hosted by organizations such as J.P. Morgan, Piper Sandler, Jefferies, H.C. Wainwright, and Morgan Stanley. These events often involve presentations or fireside chats where management discusses strategy, the transformation toward a rare disease–focused profile, and capital allocation priorities.
By monitoring ANIP news, readers can follow developments across rare disease therapeutics, generics, branded products, clinical research, and capital markets activity, all of which shape the company’s trajectory.
ANI Pharmaceuticals (Nasdaq: ANIP) announced FDA final approval and launch of Isosorbide Mononitrate Tablet USP, 10 mg and 20 mg on April 8, 2026. The product is the generic of reference listed drug Monoket. The company said the launch targets limited‑competition markets and reflects its R&D and operational capabilities.
ANI Pharmaceuticals (Nasdaq: ANIP) announced publication (April 7, 2026) of the NEW DAY randomized Phase 4 trial of ILUVIEN (fluocinolone acetonide 0.19 mg) in Ophthalmology. The report presents safety and efficacy data for ILUVIEN as a baseline therapy for diabetic macular edema in previously steroid-treated patients.
The publication includes key safety findings: intraocular pressure elevations and high cataract incidence versus sham, and notes ILUVIEN's approved indication for DME in selected patients.
ANI Pharmaceuticals (Nasdaq: ANIP) reported record Q4 2025 net revenue of $247.1M (+29.6% YoY) and full‑year revenue of $883.4M (+43.8% YoY). Cortrophin Gel drove Rare Disease growth with Q4 revenue of $111.4M (+87.6%) and full‑year $347.8M (+75.6%).
The company posted Q4 GAAP EPS $1.18 and adjusted non‑GAAP diluted EPS $2.33, record adjusted EBITDA of $65.4M Q4 and $229.8M full year, and reaffirmed 2026 guidance targeting >$1B revenue and adjusted EBITDA $275M–$290M.
ANI Pharmaceuticals (Nasdaq: ANIP) announced that CEO Nikhil Lalwani and executive leaders will present at three investor conferences in March 2026: Raymond James (Mar 3), Leerink Partners Global Healthcare (Mar 10), and Barclays Global Healthcare (Mar 11).
Live and archived webcasts will be available via the company’s Investors section, with replays accessible for 90 days.
ANI Pharmaceuticals (Nasdaq: ANIP) will release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, before the market opens. A conference call and live webcast at 8:00 a.m. ET will discuss the results, with replay available for 12 months.
Executives on the call include President and CEO Nikhil Lalwani, SVP Finance and CFO Stephen P. Carey, and Head of Rare Disease Chris Mutz. The webcast and replay will be available under Investors > Events and Presentations at www.anipharmaceuticals.com. Dial-in details include toll-free U.S. access and Conference ID 5230834.
ANI Pharmaceuticals (Nasdaq: ANIP) reported preliminary, unaudited full year 2025 results and provided full year 2026 guidance on Jan 12, 2026. ANI expects 2025 total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS to be within or above prior guidance ranges of $854M–$873M, $221M–$228M, and $7.37–$7.64, respectively. Cortrophin Gel net revenues were approximately $347.8M in 2025 (up 76% YoY) and $111.4M in Q4 2025 (up 88% YoY). 2026 guidance: $1,055M–$1,115M total net revenues; Cortrophin Gel $540M–$575M; adjusted non-GAAP EBITDA $275M–$290M; adjusted non-GAAP diluted EPS $8.83–$9.34. ANI expects Rare Disease to be ~60% of 2026 revenue, plans a ~90-person Rare Disease expansion, and will present at the J.P. Morgan Healthcare Conference on Jan 13, 2026.
ANI Pharmaceuticals (Nasdaq: ANIP) announced that CEO Nikhil Lalwani will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 at 3:00 p.m. PT / 6:00 p.m. ET.
The presentation will be available via a live webcast and an archived replay on the company website under Investors > Events and Presentations. The replay will be accessible for 30 days.
ANI Pharmaceuticals (Nasdaq: ANIP) announced on December 2, 2025 the formation of the FutureVision Advisory Council to guide its ophthalmology and retina franchise within the Rare Disease business.
The council comprises seven retina and three uveitis specialists, co‑led by Arshad M. Khanani, MD (Principal Retina Advisor and Chair) and Peter Y. Chang, MD (Principal Uveitis Advisor and Chair). The council will advise on strategic advancement of current products, including ILUVIEN and Cortrophin Gel, and on development priorities to support patient care.
ANI Pharmaceuticals (Nasdaq: ANIP) announced a Board leadership change on Dec 1, 2025. Patrick D. Walsh has stepped down as Chairman and will retire from the board after completing his current term at the Company’s 2026 Annual Meeting of Stockholders. The Board unanimously elected Thomas J. Haughey, a director since May 2018, as the next Chairman. Mr. Haughey will relinquish the role of Chair of the Audit and Finance Committee and remain on that committee and the Nominating and Corporate Governance Committee.
Jeanne Thoma, a director since August 2020, will become Chair of the Audit and Finance Committee. Management framed the transition as orderly and focused on continuity while the company expands its Rare Disease business.
ANI Pharmaceuticals (Nasdaq: ANIP) announced that Chief Executive Officer Nikhil Lalwani will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 2:00 p.m. ET. The event will be available live and via archived webcast on the company website under Investors > Events and Presentations. The replay will be accessible for 90 days following the live presentation.